Didanosine adverse reactions: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 9: | Line 9: | ||
*:[[Pancreatitis]] | *:[[Pancreatitis]] | ||
*:Lactic acidosis/severe hepatomegaly with steatosis | *: Lactic acidosis/severe hepatomegaly with steatosis | ||
*:Hepatic toxicity | *: Hepatic toxicity | ||
*:Non-cirrhotic portal hypertension | *: Non-cirrhotic portal hypertension | ||
*:[[Peripheral neuropathy]] | *: [[Peripheral neuropathy]] | ||
*:Retinal changes and [[optic neuritist]] | *: Retinal changes and [[optic neuritist]] | ||
==References== | ==References== | ||
Revision as of 20:22, 1 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Adverse Reactions
The following adverse reactions are discussed in greater detail in other sections:
- Pancreatitis
- Lactic acidosis/severe hepatomegaly with steatosis
- Hepatic toxicity
- Non-cirrhotic portal hypertension
- Peripheral neuropathy
- Retinal changes and optic neuritist
References
Adapted from the FDA Package Insert.